IGXT (MC $32 M) 2 FDA Approvals coming + 2 new NDA filings in 4Q =10+ Bagger Gem

Discussion in 'Stock picks and trading strategies' started by DollarChamp, Jul 19, 2016.

  1. DollarChamp

    DollarChamp Member

  2. DollarChamp

    DollarChamp Member

    Great time to load up nowafter they resubmit the NDA for Rizaport early this week .GL

    RedHill Biopharma and IntelGenx Submit New Drug Application to FDA for RIZAPORT® for Migraines..November 1, 2017
    https://finance.yahoo.com/news/redhill-biopharma-intelgenx-submit-drug-110100087.html


    Market Cap : US$48 Million / Cash US$8.2 million /very low burn-rate of ~$700K a Quarter =Cash untill 2020+ EXCLUDING payments from new partnerships ,profitability expected quickly with approval for Rizaport and Tadalafil both approval expected in 2018, if everything goes well then this stock could run to $10 even then it wouldnt be expensive .


    Intelgenx (IGXT)

    Markt-Cap $48 Million
    Cash 8.1 Million
    Price: $0.73


    FDA Decision for Rizaport(Migraine) in Q2/2018 (Peak Sales $60-80 Million)


    NDA submission for Tadalafil (erectile dysfunction) this Quarter >> FDA approval in 2H 2018 (Peak Sales $150++ Million)


    Start Phase 2a for Montulukast (Alzheimer disease) this Quarter >> Phase 2a Results in 1H/2018 (Potential BLOCKBUSTER Drug)


    Opioid dependence drug partnered with Par Pharma >> FDA approval depends on patent ruling (Peak Sales $100++ Million) 30-Month Stay already expired



    MEGA Pipeline
    http://s2.q4cdn.com/790425727/files...-Product-Portfolio-and-Pipeline-July-2017.jpg


    Presentation
    http://s2.q4cdn.com/790425727/files...TELGENX-Presentation-September-2017_final.pdf


    https://investorintel.com/sectors/biotech/biotech-intel/intelgenx-thin-film-market/
     
Loading...

Share This Page